🚀 VC round data is live in beta, check it out!
MariMed Valuation Multiples
Discover revenue and EBITDA valuation multiples for MariMed and similar public comparables like iAnthus Capital Holdings, SynBiotic, WM Tech, The Cannabist Company and more.
MariMed Overview
About MariMed
MariMed Inc is a multi-state cannabis operator, known for developing and managing state-of-the-art cultivation, production, and retail facilities. Its award-winning portfolio of cannabis brands, including Betty's Eddies, Bubby’s Baked, Vibations, InHouse, and Nature’s Heritage, sets the company apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry.
Founded
2011
HQ
Employees
832
Website
Financials (LTM)
EV
$104M
MariMed Financials
MariMed reported last 12-month revenue of $161M and EBITDA of $17M.
In the same LTM period, MariMed generated $58M in gross profit, $17M in EBITDA, and had net loss of ($15M).
Revenue (LTM)
MariMed P&L
In the most recent fiscal year, MariMed reported revenue of $160M and EBITDA of $17M.
MariMed expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $161M | XXX | $160M | XXX | XXX | XXX |
| Gross Profit | $58M | XXX | $58M | XXX | XXX | XXX |
| Gross Margin | 36% | XXX | 36% | XXX | XXX | XXX |
| EBITDA | $17M | XXX | $17M | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| EBIT Margin | (1%) | XXX | (0%) | XXX | XXX | XXX |
| Net Profit | ($15M) | XXX | ($14M) | XXX | XXX | XXX |
| Net Margin | (9%) | XXX | (9%) | XXX | XXX | XXX |
| Net Debt | — | — | $64M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
MariMed Stock Performance
MariMed has current market cap of $27M, and enterprise value of $104M.
Market Cap Evolution
MariMed's stock price is $0.07.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $104M | $27M | -2.9% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMariMed Valuation Multiples
MariMed trades at 0.6x EV/Revenue multiple, and 6.1x EV/EBITDA.
EV / Revenue (LTM)
MariMed Financial Valuation Multiples
As of April 18, 2026, MariMed has market cap of $27M and EV of $104M.
Equity research analysts estimate MariMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MariMed has a P/E ratio of (1.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $27M | XXX | $27M | XXX | XXX | XXX |
| EV (current) | $104M | XXX | $104M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 6.1x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBIT | (79.3x) | XXX | (137.7x) | XXX | XXX | XXX |
| EV/Gross Profit | 1.8x | XXX | 1.8x | XXX | XXX | XXX |
| P/E | (1.8x) | XXX | (1.9x) | XXX | XXX | XXX |
| EV/FCF | 34.8x | XXX | 15.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified MariMed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
MariMed Margins & Growth Rates
MariMed's revenue in the last 12 month grew by 3%.
MariMed's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
MariMed's rule of 40 is 12% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MariMed's rule of X is 14% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
MariMed Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 12% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 14% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 3% | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 17% | XXX | 34% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
MariMed Public Comps
See public comps and valuation multiples for other Cannabis comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| MariMed | XXX | XXX | XXX | XXX | XXX | XXX |
| iAnthus Capital Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| WM Tech | XXX | XXX | XXX | XXX | XXX | XXX |
| The Cannabist Company | XXX | XXX | XXX | XXX | XXX | XXX |
| Planet 13 | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MariMed M&A Activity
MariMed acquired XXX companies to date.
Last acquisition by MariMed was on XXXXXXXX, XXXXX. MariMed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by MariMed
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMariMed Investment Activity
MariMed invested in XXX companies to date.
MariMed made its latest investment on XXXXXXXX, XXXXX. MariMed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by MariMed
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout MariMed
| When was MariMed founded? | MariMed was founded in 2011. |
| Where is MariMed headquartered? | MariMed is headquartered in United States. |
| How many employees does MariMed have? | As of today, MariMed has over 832 employees. |
| Who is the CEO of MariMed? | MariMed's CEO is Robert Fireman. |
| Is MariMed publicly listed? | Yes, MariMed is a public company listed on OTC Pink Sheets. |
| What is the stock symbol of MariMed? | MariMed trades under MRMD ticker. |
| When did MariMed go public? | MariMed went public in 2012. |
| Who are competitors of MariMed? | MariMed main competitors are iAnthus Capital Holdings, SynBiotic, WM Tech, The Cannabist Company. |
| What is the current market cap of MariMed? | MariMed's current market cap is $27M. |
| What is the current revenue of MariMed? | MariMed's last 12 months revenue is $161M. |
| What is the current revenue growth of MariMed? | MariMed revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of MariMed? | Current revenue multiple of MariMed is 0.6x. |
| Is MariMed profitable? | Yes, MariMed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MariMed? | MariMed's last 12 months EBITDA is $17M. |
| What is MariMed's EBITDA margin? | MariMed's last 12 months EBITDA margin is 11%. |
| What is the current EV/EBITDA multiple of MariMed? | Current EBITDA multiple of MariMed is 6.1x. |
| What is the current FCF of MariMed? | MariMed's last 12 months FCF is $3M. |
| What is MariMed's FCF margin? | MariMed's last 12 months FCF margin is 2%. |
| What is the current EV/FCF multiple of MariMed? | Current FCF multiple of MariMed is 34.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.